Abbott Laboratories (ABT) Q4 2019 earnings summary

Executive summary

• 2019 worldwide sales were $31.9B, with 7.7% organic growth; adjusted EPS rose 12.5% to $3.24, at the high end of guidance.

• All four major businesses contributed to results; FreeStyle Libre users reached ~2 million worldwide, and MitraClip organic sales grew 30%.

Financial highlights

• Net sales were $31.904B, up from $30.578B in 2018; reported sales growth was 4.3%, while organic sales growth was 7.7%.

• Net earnings were $3.687B vs. $2.368B; diluted EPS from continuing operations was $2.06 vs. $1.31.

• Operating earnings were $4.532B vs. $3.650B; gross profit margin was 52.5% vs. 51.3%.

• Q4 sales were $8.314B vs. $7.765B; continuing-operations earnings were $1.049B vs. $655M, and diluted EPS was $0.59 vs. $0.37.

• Operating cash flow was $6.136B; capital expenditures were $1.638B.

Outlook and guidance

• 2020 priorities include expanding Alinity adoption, growing diabetes care, structural heart, electrophysiology and heart failure, and extending nutrition and emerging-market medicine portfolios.

• R&D spending is expected to approximate 7.0% of sales in 2020; no individual development project is expected to be material to cash flows or results over the next five years.

• Operating cash flow is expected to continue exceeding capital expenditures and cash dividends; planned 2020 pension funding is ~$387M.